Development of a Drosophila melanogaster spliceosensor system for in vivo high-throughput screening in myotonic dystrophy type 1

DMM Disease Models and Mechanisms

Volumn 7, Issue 11, 2014, Pages 1297-1306

  García Alcover, Irma ^a   Colonques Bellmunt, Jordi ^a   Garijo, Raquel ^a,c   Tormo, José R ^a,d   Artero, Rubén ^a,b   Álvarez Abril, Mari Carmen ^a   Castel, Arturo López ^a,d   Pérez Alonso, Manuel ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Biomedical Research Institute Hospital Clinic de Valencia INCLIVA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Health Sciences Technology Park   (Spain)

Author keywords

In vivo screening; Luciferase; Minigene; Myotonic dystrophy; Splicing

Indexed keywords

LUCIFERASE; MESSENGER RNA PRECURSOR; MUSCLEBLIND LIKE PROTEIN 1; MUSCLEBLIND LIKE PROTEIN 3; RNA; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ACCURACY; ALTERNATIVE RNA SPLICING; ARTICLE; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; GAIN OF FUNCTION MUTATION; GENE IDENTIFICATION; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MYOTONIC DYSTROPHY; NONHUMAN; REPORTER GENE; REPRODUCIBILITY; SPLICEOSENSOR; SPLICEOSOME; SPLICING DEFECT; SPLICING MODULATOR; TRANSGENE; TRANSGENIC DROSOPHILA; VALIDITY; ANIMAL; GENETICS; VALIDATION STUDY;

DROSOPHILA MELANOGASTER; EUKARYOTA;

ALTERNATIVE SPLICING; ANIMALS; DROSOPHILA MELANOGASTER; HIGH-THROUGHPUT SCREENING ASSAYS; MYOTONIC DYSTROPHY;

EID: 84919968188     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.016592     Document Type: Article

References (50)

1. Arslan, A. D., He, X., Wang, M., Rumschlag-Booms, E., Rong, L. and Beck, W. T. (2013). A high-throughput assay to identify small-molecule modulators of alternative pre-mRNA splicing. J. Biomol. Screen. 18, 180-190.
2. Beard, G. S., Bridger, J. M., Kill, I. R. and Tree, D. R. (2008). Towards a Drosophila model of Hutchinson-Gilford progeria syndrome. Biochem. Soc. Trans. 36, 1389-1392.
3. Begemann, G., Paricio, N., Artero, R., Kiss, I., Pérez-Alonso, M. and Mlodzik, M. (1997). muscleblind, a gene required for photoreceptor differentiation in Drosophila, encodes novel nuclear Cys3His-type zinc-finger-containing proteins. Development 124, 4321-4331.
4. Brand, A. H. and Perrimon, N. (1993). Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118, 401-415.
5. Calarco, J. A., Zhen, M. and Blencowe, B. J. (2011). Networking in a global world: establishing functional connections between neural splicing regulators and their target transcripts. RNA 17, 775-791.
6. Childs-Disney, J. L., Parkesh, R., Nakamori, M., Thornton, C. A. and Disney, M. D. (2012). Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem. Biol. 7, 1984-1993.
7. Childs-Disney, J. L., Stepniak-Konieczna, E., Tran, T., Yildirim, I., Park, H., Chen, C. Z., Hoskins, J., Southall, N., Marugan, J. J., Patnaik, S. et al. (2013). Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat. Commun. 4, 2044.
8. Clower, C. V., Chatterjee, D., Wang, Z., Cantley, L. C., Vander Heiden, M. G. and Krainer, A. R. (2010). The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. USA 107, 1894-1899.
9. Crowe, A., Huang, W., Ballatore, C., Johnson, R. L., Hogan, A. M., Huang, R., Wichterman, J., McCoy, J., Huryn, D., Auld, D. S. et al. (2009). Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48, 7732-7745.
10. Demontis, F., Piccirillo, R., Goldberg, A. L. and Perrimon, N. (2013). Mechanisms of skeletal muscle aging: insights from Drosophila and mammalian models. Dis. Model. Mech. 6, 1339-1352.
11. García-Casado, M. Z., Artero, R. D., Paricio, N., Terol, J. and Pérez-Alonso, M. (2002). Generation of GAL4-responsive muscleblind constructs. Genesis 34, 111-114.
12. García-López, A., Monferrer, L., Garcia-Alcover, I., Vicente-Crespo, M., Alvarez-Abril, M. C. and Artero, R. D. (2008). Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS One 3, e1595.
13. García-López, A., Llamusí, B., Orzáez, M., Pérez-Payá, E. and Artero, R. D. (2011). In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc. Natl. Acad. Sci. USA 108, 11866-11871.
14. Giacomotto, J. and Ségalat, L. (2010). High-throughput screening and small animal models, where are we? Br. J. Pharmacol. 160, 204-216.
15. Grammatikakis, I., Goo, Y. H., Echeverria, G. V. and Cooper, T. A. (2011). Identification of MBNL1 and MBNL3 domains required for splicing activation and repression. Nucleic Acids Res. 39, 2769-2780.
16. Havens, M. A., Duelli, D. M. and Hastings, M. L. (2013). Targeting RNA splicing for disease therapy. Wiley Interdiscip. Rev. RNA 4, 247-266.
17. Irion, U. (2012). Drosophila muscleblind codes for proteins with one and two tandem zinc finger motifs. PLoS ONE 7, e34248.
18. Ketley, A., Chen, C. Z., Li, X., Arya, S., Robinson, T. E., Granados-Riveron, J., Udosen, I., Morris, G. E., Holt, I., Furling, D. et al. (2014). High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Hum. Mol. Genet. 23, 1551-1562.
19. Kreyszig, E. (1979). Applied Mathematics. Hoboken, NJ: John Wiley & Sons.
20. Lloyd, T. E. and Taylor, J. P. (2010). Flightless flies: Drosophila models of neuromuscular disease. Ann. N. Y. Acad. Sci. 1184, e1-e20.
21. Machuca-Tzili, L., Thorpe, H., Robinson, T. E., Sewry, C. and Brook, J. D. (2006). Flies deficient in Muscleblind protein model features of myotonic dystrophy with altered splice forms of Z-band associated transcripts. Hum. Genet. 120, 487-499.
22. Mosqueira, M., Willmann, G., Ruohola-Baker, H. and Khurana, T. S. (2010). Chronic hypoxia impairs muscle function in the Drosophila model of Duchenne's muscular dystrophy (DMD). PLoS ONE 5, e13450.
23. Mount, S. M., Burks, C., Hertz, G., Stormo, G. D., White, O. and Fields, C. (1992). Splicing signals in Drosophila: intron size, information content, and consensus sequences. Nucleic Acids Res. 20, 4255-4262.
24. Nazir, A., Mukhopadhyay, I., Saxena, D. K. and Chowdhuri, D. K. (2003). Evaluation of the no observed adverse effect level of solvent dimethyl sulfoxide in Drosophila melanogaster. Toxicol. Mech. Methods 13, 147-152.
25. O'Leary, D. A., Vargas, L., Sharif, O., Garcia, M. E., Sigal, Y. J., Chow, S. K., Schmedt, C., Caldwell, J. S., Brinker, A. and Engels, I. H. (2010). HTS-compatible patient-derived cell-based assay to identify small molecule modulators of aberrant splicing in Myotonic Dystrophy type 1. Curr Chem Genomics 4, 9-18.
26. Oana, K., Oma, Y., Suo, S., Takahashi, M. P., Nishino, I., Takeda, S. and Ishiura, S. (2013). Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice. Sci. Rep. 3, 2142.
27. Pandey, U. B. and Nichols, C. D. (2011). Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol. Rev. 63, 411-436.
28. Parkesh, R., Childs-Disney, J. L., Nakamori, M., Kumar, A., Wang, E., Wang, T., Hoskins, J., Tran, T., Housman, D., Thornton, C. A. et al. (2012). Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J. Am. Chem. Soc. 134, 4731-4742.
29. Philips, A. V., Timchenko, L. T. and Cooper, T. A. (1998). Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280, 737-741.
30. Piccirillo, R., Demontis, F., Perrimon, N. and Goldberg, A. L. (2014). Mechanisms of muscle growth and atrophy in mammals and Drosophila. Dev. Dyn. 243, 201-215.
31. Ranum, L. P. and Cooper, T. A. (2006). RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 29, 259-277.
32. Santoro, M., Masciullo, M., Bonvissuto, D., Bianchi, M. L., Michetti, F. and Silvestri, G. (2013). Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2. Mol. Cell. Biochem. 380, 259-265.
33. Savkur, R. S., Philips, A. V. and Cooper, T. A. (2001). Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 29, 40-47.
34. Singh, R. K. and Cooper, T. A. (2012). Pre-mRNA splicing in disease and therapeutics. Trends Mol. Med. 18, 472-482.
35. Takeuchi, A., Hosokawa, M., Nojima, T. and Hagiwara, M. (2010). Splicing reporter mice revealed the evolutionally conserved switching mechanism of tissue-specific alternative exon selection. PLoS ONE 5, e10946.
36. Timmerman, C. and Sanyal, S. (2012). Behavioral and electrophysiological outcomes of tissue-specific Smn knockdown in Drosophila melanogaster. Brain Res. 1489, 66-80.
37. Tixier, V., Bataillé, L. and Jagla, K. (2010). Diversification of muscle types: recent insights from Drosophila. Exp. Cell Res. 316, 3019-3027.
38. Udd, B. and Krahe, R. (2012). The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 11, 891-905.
39. Udd, B., Meola, G., Krahe, R., Wansink, D. G., Bassez, G., Kress, W., Schoser, B. and Moxley, R. (2011). Myotonic dystrophy type 2 (DM2) and related disorders report of the 180th ENMC workshop including guidelines on diagnostics and management 3-5 December 2010, Naarden, The Netherlands. Neuromuscul. Disord. 21, 443-450.
40. Venables, J. P., Tazi, J. and Juge, F. (2012). Regulated functional alternative splicing in Drosophila. Nucleic Acids Res. 40, 1-10.
41. Vicente, M., Monferrer, L., Poulos, M. G., Houseley, J., Monckton, D. G., O'dell, K. M., Swanson, M. S. and Artero, R. D. (2007). Muscleblind isoforms are functionally distinct and regulate alpha-actinin splicing. Differentiation 75, 427-440.
42. Wang, Z. and Burge, C. B. (2008). Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 14, 802-813.
43. Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A. and Berglund, J. A. (2009). Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc. Natl. Acad. Sci. USA 106, 18551-18556.
44. Wheeler, T. M., Sobczak, K., Lueck, J. D., Osborne, R. J., Lin, X., Dirksen, R. T. and Thornton, C. A. (2009). Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325, 336-339.
45. Wheeler, T. M., Leger, A. J., Pandey, S. K., MacLeod, A. R., Nakamori, M., Cheng, S. H., Wentworth, B. M., Bennett, C. F. and Thornton, C. A. (2012). Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115.
46. Xu, Z., Poidevin, M., Li, X., Li, Y., Shu, L., Nelson, D. L., Li, H., Hales, C. M., Gearing, M., Wingo, T. S. et al. (2013). Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc. Natl. Acad. Sci. USA 110, 7778-7783.
47. Younis, I., Berg, M., Kaida, D., Dittmar, K., Wang, C. and Dreyfuss, G. (2010). Rapid-response splicing reporter screens identify differential regulators of constitutive and alternative splicing. Mol. Cell. Biol. 30, 1718-1728.
48. Yuan, Y., Compton, S. A., Sobczak, K., Stenberg, M. G., Thornton, C. A., Griffith, J. D. and Swanson, M. S. (2007). Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res. 35, 5474-5486.
49. Zhang, J. H., Chung, T. D. Y. and Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening. J. Biomol. Screen. 4, 67-73.
50. Zheng, S., Damoiseaux, R., Chen, L. and Black, D. L. (2013). A broadly applicable high-throughput screening strategy identifies new regulators of Dlg4 (Psd-95) alternative splicing. Genome Res. 23, 998-1007.